Prix Jiangsu Recbio Technology Co., Ltd. (02179.HK)

Jiangsu Recbio Technology Co., Ltd. engages in the research and development of vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 507 full-time employees. The company went IPO on 2022-03-31. The firm is still in the research and development stage. The firm's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.